Document is current
Any future updates will be listed below
-
Authors
Amin, Alpesh N.
Menoyo, Jose
Singh, Bhupinder
Kim, Christopher S.
-
Funding
Funding for this research was provided by:
ZS Pharma, Inc., a member of the AstraZeneca family of companies (N/A)
- License Information
-
More Information
Article History
Received: 31 May 2019
Accepted: 29 October 2019
First Online: 2 December 2019
Ethics approval and consent to participate
: An institutional review board (IRB) or independent ethics committee at each participating institution approved the study (ZS-003: Liberty IRB, DeLand, FL, USA; Committee for the Protection of Human Subjects, Rhode Island Hospital, Providence, RI, USA; Doylestown Hospital IRB, Doylestown, PA, USA; UTHSCSA IRB, San Antonio, TX, USA; Bellberry HREC, Ltd., Dulwich, South Australia, Australia; Pharma Ethics (Pty) Ltd., Centurion, Gauteng, South Africa; HARMONIZE: Liberty IRB, DeLand, FL, USA; Committee for the Protection of Human Subjects, Rhode Island Hospital, Providence, RI, USA; Saint Luke’s IRB, Kansas City, MO, USA; Bellberry HREC, Ltd., Dulwich, South Australia, Australia; Melbourne Health – Office for Research, The Royal Melbourne Hospital, Parkville, Victoria, Australia; Pharma Ethics (Pty) Ltd., Centurion, Gauteng, South Africa. All participants provided written informed consent to participate.
: Not applicable.
: AA has served on advisory panels for ZS Pharma Inc., a member of the AstraZeneca Group. JM and BS were employees of ZS Pharma, Inc., a member of the AstraZeneca Group, at the time of the analysis and own stock in AstraZeneca. CSK has served on advisory panels for ZS Pharma, Inc., a member of the AstraZeneca Group, and has served on panels for Actavis Pharma, Inc.
